熱門資訊> 正文
Senti Biosciences将分拆其基因电路管道
2026-07-15 19:59
- Senti Biosciences Holdings (SNTI) on Wednesday said privately held NewCo controlled by affiliates of top investor Celadon will acquire its gene-circuit pipeline, including SENTI-202.
- Equity holders are to receive a contingent value right offering up to $60M in milestone payments tied to SENTI-202 development, FDA approval, and sales.
- Senti to focus on its Regulator Dial technology platform and seek additional financing after the transaction closes.
More on Senti Biosciences
- Seeking Alpha’s Quant Rating on Senti Biosciences
- Historical earnings data for Senti Biosciences
- Financial information for Senti Biosciences
推薦文章
銀色債券2026今起認購！保底息率4.25釐，每手3年累計派息至少1,275港元
華盛早報 | 貝森特兩日救市！美債回購規模或超40億美元；Anthropic衝擊史上最大IPO；恆指季檢結果，中際旭創、長飛光纖財報今日公佈
美股前瞻 | 史詩級「軋空」來襲！比特幣升破7.2萬美元；業績股齊遇冷！沃爾瑪盤前大跌逾6%，阿里、網易均跌近4%
一圖看懂 | AI與雲業務表現強勁！阿里Q1營收2690億元，同比增9%略超預期；阿里雲外部商業化收入加速增至45%
一圖看懂 | 泡泡瑪特上半年營收171億、淨利50億均大遜預期！星星人IP逆勢暴漲580%；王寧稱計劃半年內大額回購20-50億
Moderna暴漲177%！mRNA癌症疫苗迎來「ChatGPT時刻」？16只港美標的誰會接過下一棒？
「影子股」已暴漲90%！如何在Anthropic史上最大IPO前搶跑入局？最全攻略來了
港股異動 | 全球首個mRNA癌症疫苗三期成功落地！港股醫藥股齊衝高，康希諾生物飆升49%，雲頂新耀勁升42%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
